Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Molecular assay may help identify NSCLC patients who could benefit from...

Dr David Spigel - Sarah Cannon Research Institute, Nashville, USA

Molecular assay may help identify NSCLC patients who could benefit from adjuvant chemotherapy ( Dr David Spigel - Sarah Cannon Research Institute, Nashville, USA )

GLP-1 receptor agonists may slightly reduce risk of fourteen obesity-related...

Dr Lucas A Mavromatis - NYU Grossman School of Medicine, New York, USA

GLP-1 receptor agonists may slightly reduce risk of fourteen obesity-related cancers for diabetics ( Dr Lucas A Mavromatis - NYU Grossman School of Medicine, New York, USA )

QoL improvements ID'd in phase 3 ARANOTE trial for mHSPC

Dr Alicia Morgans - Dana-Farber Cancer Institute, Boston, USA

QoL improvements ID'd in phase 3 ARANOTE trial for mHSPC ( Dr Alicia Morgans - Dana-Farber Cancer Institute, Boston, USA )

Trastuzumab deruxtecan plus pertuzumab may delay cancer growth for some HER2...

Dr Sara Tolaney - Dana-Farber Cancer Institute, Boston, USA

Trastuzumab deruxtecan plus pertuzumab may delay cancer growth for some HER2-positive advanced breast cancers ( Dr Sara Tolaney - Dana-Farber Cancer Institute, Boston, USA )

Rusfertide shows promise for polycythemia vera treatment

Dr Andrew Kuykendall - Moffitt Cancer Center, Tampa, USA

Rusfertide shows promise for polycythemia vera treatment ( Dr Andrew Kuykendall - Moffitt Cancer Center, Tampa, USA )

Neoadjuvant gemcitabine and cisplatin improves OS in resectable biliary tract...

Dr Thorsten Oliver Goetze - The University Cancer Center (UCT), Frankfurt...

Neoadjuvant gemcitabine and cisplatin improves OS in resectable biliary tract cancer ( Dr Thorsten Oliver Goetze - The University Cancer Center (UCT), Frankfurt, Germany )

Cemiplimab reduces disease recurrence as adjuvant therapy for cutaneous...

Dr Danny Rischin - Peter MacCallum Cancer Centre, Melbourne, Australia

Cemiplimab reduces disease recurrence as adjuvant therapy for cutaneous squamous cell carcinoma ( Dr Danny Rischin - Peter MacCallum Cancer Centre, Melbourne, Australia )

ASCO 2025: Update on blood-based cancer assays

Dr Marie Wood - UCHealth University of Colorado Hospital, Aurora, USA

ASCO 2025: Update on blood-based cancer assays ( Dr Marie Wood - UCHealth University of Colorado Hospital, Aurora, USA )

Trastuzumab deruxtecan benefit for some advanced gastric cancers

Dr Kohei Shitara - National Cancer Center Hospital East, Kashiwa, Japan

Trastuzumab deruxtecan benefit for some advanced gastric cancers ( Dr Kohei Shitara - National Cancer Center Hospital East, Kashiwa, Japan )

HER2-positive breast cancer: Predicting pCR from clinicopathologic variables...

Dr Nadine M Tung - Beth Israel Deaconess Medical Center, Boston, USA

HER2-positive breast cancer: Predicting pCR from clinicopathologic variables and genomic testing ( Dr Nadine M Tung - Beth Israel Deaconess Medical Center, Boston, USA )

Tumor Treating Fields plus chemo shows OS benefit in unresectable pancreatic...

Dr Vincent Picozzi - Virginia Mason Medical Center, Seattle, USA

Tumor Treating Fields plus chemo shows OS benefit in unresectable pancreatic cancer ( Dr Vincent Picozzi - Virginia Mason Medical Center, Seattle, USA )

Abemaciclib potential therapeutic option for Kaposi sarcoma

Dr Ramya Ramaswami - National Cancer Institute, Bethesda, USA

Abemaciclib potential therapeutic option for Kaposi sarcoma ( Dr Ramya Ramaswami - National Cancer Institute, Bethesda, USA )

More from ecancer